Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome

BMC Gastroenterology

Research Article

Pietro Coccoli¹  Barbara Iovine¹  Costantino Sgamato¹  Umberto Salvatore¹  Debora Compare¹  Alba Rocco¹  Gerardo Nardone¹  Debora Angrisani¹ 

[1] Department of Clinical Medicine and Surgery, Gastroenterology Unit, University Federico II of Naples, Via S. Pansini 5, 80131, Naples, Italy;

关键词: Post-infectious irritable bowel syndrome;    Probiotics;    Postbiotic;   

DOI  :  10.1186/s12876-017-0605-x

 received in 2016-11-09, accepted in 2017-03-28,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe evidence on the role of gut microbiota in post-infectious irritable bowel syndrome (PI-IBS) is convincing. Lactobacillus spp. positively affect IBS symptoms, although the mechanisms through which probiotics exert their beneficial effects are largely unknown. The aim of the study is to evaluate the role of Lactobacillus casei DG (LC-DG) and its postbiotic (PB) in modulating the inflammatory/immune-response in PI-IBS in an ex-vivo organ culture model.MethodsEx vivo cultures of ileal and colonic mucosa from 10 PI-IBS, diarrhea predominant subtype (D) patients, and 10 healthy controls (HC) were treated with LPS, LC-DG and PB. Interleukin (IL)-1α, IL-6, IL-8 and IL-10 mRNA levels were assessed by real-time PCR and Toll like receptor 4 (TLR-4) protein expression by Western blotting.ResultsAt baseline, IL-1α, IL-6 and IL-8 mRNA levels as well as TLR-4 protein expression were significantly higher while IL-10 mRNA levels were lower in PI-IBS D than in HC in both ileum and colon. LC-DG and PB significantly reduced the mRNA levels of pro-inflammatory cytokines and TLR-4 while increased that of IL-10 after LPS stimulation. The protective effect was more pronounced for PB than LC-DG treatment.ConclusionLC-DG and its PB attenuate the inflammatory mucosal response in an ex-vivo organ culture model of PI-IBS D.

【 授权许可】

CC BY   
© The Author(s). 2017